retatrutide ly3437943 triple agonist gip glp-1 glucagon LY3437943, a novel glucagon, GIP, and receptor for glycemic control and weight loss: From discovery to clinical proof of concept Retatrutide Dosage & Titration: Complete

GLP-1RA only reduced the risk of nonfatal stroke

It caused tumors in animal studies

GLP-1 receptor agonists got their start in an unlikely place: the mouth of a lizard

NPR Pharmaceuticals Correspondent Sydney Lupkin chats about these experimental pills with host Emily Kwong.Check out more of NPRs coverage about GLP-1s.Interested in more health stories

Dual GIP-GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential Marie Bastin, Fabrizio Andreelli Diabetology-Metabolism Department, Sorbonne Universit, ICAN, Assistance Publique Hpitaux de Paris, Piti-Salptrire Hospital, Paris, F-75013, FranceCorrespondence: Fabrizio AndreelliDiabetology-Metabolism Department, Piti-Salptrire Hospital, 47-83 Boulevard de lHpital, Paris cedex 13, 75951, FranceEmail [email protected]: The need for efficient and safe therapy to improve such metabolic diseases as obesity and type 2 diabetes mellitus is currently unmet